ZLAB has had a remarkable week, posting a 27.6% gain to $23.32 after first-in-human data for ZL-1310 in advanced small cell lung cancer delivered a positive surprise that caught short sellers badly positioned.
The catalyst was Wednesday's earnings release, which doubled as a clinical data readout. ZL-1310 generated a one-day move of roughly 27% — the single largest daily swing in recent history for the stock. That kind of print compresses a thesis quickly. Short interest had been on a declining trend since mid-July, when it peaked near 8.3 million shares and has since fallen to approximately 6.3 million. The move down in borrowed shares over the past six weeks, combined with a 27% price spike, means shorts who held through the announcement absorbed meaningful mark-to-market pain in a compressed window.
The lending market confirms the pressure is real but not yet extreme. Availability has tightened sharply this week — dropping from around 74% a week ago to 42.7% now, meaning only about four shares remain available to borrow for every ten already lent out. That is firmly in "tight" territory. Cost to borrow, however, has actually eased — falling 19% on the week to 2.33% — which suggests the squeeze dynamic is more about price-driven pain than a structural shortage of borrow supply. The ORTEX short score of 70.2 places ZLAB in the upper band of bearish positioning relative to the broader universe, ranking in just the 12th percentile on short score rank (lower is more bearish). Availability ranks in the 4th percentile for the sector, a signal that the lending pool is genuinely constrained relative to biotech peers. Options positioning adds another layer: the put/call ratio of 4.93 runs well above its 20-day average of 4.38, though at roughly 1.4 standard deviations above the mean it has not yet reached the extremes seen earlier in the year (the 52-week high was 10.02). Puts continue to dominate the options book, but the skew has been there for weeks — this is a structurally hedged name, not a fresh spike in fear.
Analyst conviction shifted immediately after the data. Citigroup's Yigal Nochomovitz, one of the most active names on this stock, raised his target to $45 from $44 while maintaining his Buy rating — a modest adjustment relative to the magnitude of the move, suggesting he sees further upside but is not yet dramatically revising the bull case. The consensus mean target of $33.52 is now above the current price of $23.32, implying about 44% upside to the Street's central estimate. That said, context matters: several of the recent target changes in early 2026 were cuts. JPMorgan lowered to $32 in March, Cantor Fitzgerald slashed from $55 to $37 in February. The Street has been broadly bullish on direction but has been trimming numbers for most of this year. This week's data may prompt a round of upward revisions — but the consensus target is already pricing in a significant recovery from current levels. The stock is loss-making (PE of -10.8, EV/EBITDA of -9.5), so traditional valuation multiples carry limited weight here. The price-to-book of 4.75 has risen sharply on the week alongside the price surge. The bull case centres on ZL-1310's potential in SCLC and the broader oncology pipeline; the bear case points to commercialization risk, competition from larger pharmaceutical companies, and operational exposure to the Chinese regulatory environment.
Institutional positioning shows some interesting recent movement. TCG Crossover, the largest reported holder at 5.26% of shares, added its entire stake as of the June filing — a new position from a crossover fund that typically bets on late-stage clinical names ahead of inflection events. FMR added roughly 1 million shares in a filing dated July 9. Morgan Stanley reported adding 443,000 shares as of July 1. The cluster of institutional buying ahead of this week's readout is notable context. CEO and Founder Samantha Du has been selling modest amounts under what appears to be a scheduled plan — $559,000 in net sales across June, against awards of roughly 76,000 shares — not a signal of concern on its own given the award activity accompanying the sales.
The next formal earnings event is slated for November 6. Between now and then, the conversation shifts entirely to whether ZL-1310's first-in-human data translates into a defined development path for SCLC and what additional clinical milestones ZLAB can deliver to sustain a stock that, even after this week's surge, trades at roughly half the price targets that prevailed just six months ago.
See the live data behind this article on ORTEX.
Open ZLAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
